Antitrust Alert: Korea Fair Trade Commission Announces Focus on Perceived Antitrust Abuses of Intellectual Property by IT and Pharmaceutical Companies
This initiative follows the KFTC's high profile enforcement actions against Qualcomm, Microsoft, and Intel for allegedly anticompetitive licensing, bundling and rebate practices relating to IT patents and products licensed and sold in Korea. The KFTC focus on the pharmaceutical industry seems to echo the European Commission's current inquiry into competition in that sector. In a preliminary report issued in November 2008, the EC found "evidence that [sellers and licensees of brand name pharmaceutical products] have engaged in practices with the objective of delaying or blocking market entry of competing medicines.” (See Jones Day Antitrust Alert, "European Commission Issues Preliminary Report on Pharmaceutical Sector Inquiry" (December 2008).
Companies selling IT and pharmaceutical products in Korea or licensing patents in those fields in Korean markets should be familiar with recent developments: the relevant recent enforcement actions of the KFTC, the applicable provisions of the Korea Monopoly Regulation and Fair Trade Act ("MARFTA"), and Guidelines promulgated under MARFTA, in particular the Guideline for Review of the Abuse of a Market Dominant Position ("Dominance Guideline") and the Guideline for Review of Unfair Trade Practices ("Unfair Trade Practices Guideline").In particular, it should be noted that Korean antitrust law regards a reduction in the number of competitors as a "competition restricting effect" which in turn constitutes a "hindering" of fair trade, which is one of the statutory criteria for judging whether conduct violates the prohibition of unfair business practices in MARFTA Article 23. This explicit concern for preservation of the number of competitors in a market contrasts with U.S. antitrust approach, which focuses on the effect of competitive conduct on consumer welfare, including prices and output. As such, conduct that may tend to drive competitors from a market, or to exclude potential competitors from entering a market, even if considered procompetitive under U.S. antitrust law, may run afoul of Korean law. In light of the KFTC's avowed focus on competitive conduct in the IT and pharmaceutical sectors, companies in these industries should consider carefully the effects of the terms of sales and licensing transactions involving the Korean markets, including the effects on actual and potential competitors.
Lawyer ContactsJones Day prepares summaries of significant antitrust enforcement, litigation, and policy events as a service to clients and interested readers, to provide timely insight on antitrust and competition law developments relevant to business, but not as legal advice on any specific matter. Please visit our Publication Request form to add your name to our distribution list For more information, please contact your principal Jones Day representative or either of the lawyers listed below.
H. Stephen Harris, Jr.